The company is being liquidated via ABC (state-law alternative to Chapter 7 bankruptcy). Common equity is effectively worthless. Monitor PT Liquidation, LLC for any creditor distribution updates; no further trading in PTPI common stock is expected.
Price Chart
Executive Summary
Petros Pharmaceuticals has entered into a General Assignment for the Benefit of Creditors (ABC) under California law, effectively liquidating the company. All assets have been assigned to PT Liquidation, LLC for creditor benefit, substantially all operations have ceased, and the company states it can no longer continue as a going concern. The entire board of directors resigned, the President/CCO was terminated, and the CAO/CFO resigned, with all outstanding obligations including Series A Convertible Preferred Stock redemption triggered.
Key Facts
- On September 30, 2026, Petros Pharmaceuticals entered into a General Assignment for the Benefit of Creditors (ABC) under California law, assigning all assets to PT Liquidation, LLC as Assignee.
- The ABC constitutes a liquidation event; the company has ceased substantially all business operations and states it no longer has the ability to continue as a going concern.
- The ABC triggered defaults under contractual obligations and a mandatory immediate redemption of all outstanding Series A Convertible Preferred Stock.
- Executive Chairman Joshua N. Silverman, Director Bruce T. Bernstein, and Director Wayne R. Walker resigned from the Board effective September 30, 2026.
- President and Chief Commercial Officer Fady Boctor was terminated on September 30, 2026.
- Chief Accounting Officer, Principal Financial Officer, and Principal Accounting Officer Robert Weinstein resigned effective September 30, 2026 at 5:30 p.m. Eastern time.
- The resignations/termination were stated as not resulting from any disagreement with the company on operations, policies, or practices.
Financial Impact
Total liquidation — all assets assigned to creditor liquidation trust; shareholder equity expected to be wiped out. No specific asset or liability figures provided in the filing.
Risk Factors
- Common stock likely to be delisted and become worthless
- Series A Convertible Preferred Stock mandatory redemption likely not payable given liquidation
- Creditor recoveries uncertain — no asset/liability figures disclosed
- No ongoing business operations — zero revenue going forward
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-112399 |
| Document: 0001104659-26-112399-index-headers.html | 0001104659-26-112399 |
| Document: 0001104659-26-112399-index.html | 0001104659-26-112399 |
| Document: 0001104659-26-112399.txt | 0001104659-26-112399 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 26d ago | 8-K | $0.003000 $0.003000 | · 0.00% | ▲ +1.30% | $0.001900 (+36.67%) |
Jun 25, 2026 17w ago | 3 | $0.006000 $0.005000 | ▼ −16.67% | ▼ −18.83% | $0.001900 (−68.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers